All News

CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma

“If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.”

In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.

In this episode of "Oncology Peer Review On-The-Go," Amy Comander, MD, spoke with CancerNetwork regarding important developments in breast cancer that took place in 2021 and key clinical trials that read out throughout the year.

CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma experienced a better overall survival when treated with adjuvant chemotherapy.

Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings.

Fam-trastuzumab deruxtecan-nxki, which was granted a priority review designation, appears to have potential for patients with HER2-positive unresectable/metastatic breast cancer.

Women diagnosed with ovarian cancer were reported to have longer waiting times for treatment vs other cancer types with the exception of kidney cancer.

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

CancerNetwork® spoke with Rafael Fonseca, MD, about findings from a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.

Two-year overall survival increased from period between 2000 and 2004 to period between 2015 and 2019 for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about key takeaways learned in the treatment of myelofibrosis during 2021.

Research suggests a new HER2DX assay is potentially able to accurately predict risk of recurrence for patients with early-stage HER2-positive breast cancer.

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.

Investigators reported that the development of cutaneous immune-related adverse effects has a strong association with response in survival among patients with cancer treated with immunotherapy.

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Use of a multimedia education platform appeared to compliment traditional education methods and provide complementary information on treatment and recovery for those with head and neck cancer.

Patients diagnosed with early-stage ovarian cancer who are treated with novel targeted therapies may experience better overall survival and less financial toxicity compared with those who have late-stage disease.

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A study conducted by Mount Sinai investigators determined that the co-occurrence of t(4;14) and 1q gain was effective at identifying newly diagnosed patients with multiple myeloma who were at high risk of relapse.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about clinical trials and treatments being utilized in 2022.

Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

From 2003 to 2016, investigators noted that incidence of multiple myeloma varied by racial and ethnic group, as well as sex.

A bi-specific anti-CD19/CD20 CAR T-cell therapy, C-CAR039, received a regenerative medicine advanced therapy designation and fast track designation from the FDA for treating patients with relapsed/refractory diffuse large B cell lymphoma.

A pooled analysis indicated that patients who were 80 years or older had efficacious responses to targeted therapies for chronic lymphocytic leukemia regardless of coexisting conditions and organ dysfunction.

At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.

Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.